Abstract
Background: Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor, with an incidence of 3.19 cases per 100,000 person years and remarkably poor prognosis showing a 5-year survival rate of 4-5%, and only a 26-33% survival rate at 2 years in clinical trials.
Objective: In this paper, we review the different types of treatment modalities based on the relevant databases. Methods of diagnosis will be described briefly.
Method: Systemic compilation of the relevant literature.
Results & Conclusion: Today's treatments cannot cure GBM patients but only extend their overall survival. The use of chemoradiation, immunotherapy, and radio sensitizers as an adjuvant therapy cannot reduce the high rates of recurrence within a few months after treatment. Radiotherapy will remain the backbone of the treatment but new treatment modalities must be developed.
Keywords: Biologic agent, chemotherapy, glioblastoma multiforme, immunotherapy, radiation therapy, vaccination.
Current Medicinal Chemistry
Title:Glioblastoma Multiforme, Diagnosis and Treatment; Recent Literature Review
Volume: 24 Issue: 27
Author(s): Ron Batash , Noam Asna *, Pamela Schaffer, Nicole Francis and Moshe Schaffer
Affiliation:
- Barzilai Medical Center, Department of Oncology, Ashkelon,Israel
Keywords: Biologic agent, chemotherapy, glioblastoma multiforme, immunotherapy, radiation therapy, vaccination.
Abstract: Background: Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor, with an incidence of 3.19 cases per 100,000 person years and remarkably poor prognosis showing a 5-year survival rate of 4-5%, and only a 26-33% survival rate at 2 years in clinical trials.
Objective: In this paper, we review the different types of treatment modalities based on the relevant databases. Methods of diagnosis will be described briefly.
Method: Systemic compilation of the relevant literature.
Results & Conclusion: Today's treatments cannot cure GBM patients but only extend their overall survival. The use of chemoradiation, immunotherapy, and radio sensitizers as an adjuvant therapy cannot reduce the high rates of recurrence within a few months after treatment. Radiotherapy will remain the backbone of the treatment but new treatment modalities must be developed.
Export Options
About this article
Cite this article as:
Batash Ron , Asna Noam*, Schaffer Pamela, Francis Nicole and Schaffer Moshe , Glioblastoma Multiforme, Diagnosis and Treatment; Recent Literature Review, Current Medicinal Chemistry 2017; 24 (27) . https://dx.doi.org/10.2174/0929867324666170516123206
DOI https://dx.doi.org/10.2174/0929867324666170516123206 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Advances in the Development of Anticancer HSP-based Vaccines
Current Medicinal Chemistry Importance of Aquaporins in the Physiopathology of Brain Edema
Current Pharmaceutical Design Recent Research Progress on Magnetic Nanocomposites with Silica Shell Structures Preparation and Nanotheranostic Applications
Recent Patents on Nanotechnology Mitochondria in Cancer Stem Cells: A Target for Therapy
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery The Role of PEDF in Tumor Growth and Metastasis
Current Molecular Medicine Effect of Salinomycin on Expression Pattern of Genes Associated with Apoptosis in Endometrial Cancer Cell Line
Current Pharmaceutical Biotechnology Immuno-Isolation in Cancer Gene Therapy
Current Gene Therapy Design and Synthesis of Tetrahydroisoquinoline Derivatives as Anti-Angiogenesis and Anti-Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry Apoptosis Pathways and Neuroblastoma Therapy
Current Pharmaceutical Design Editorial (BIOQUEST India: A Global Biotechnology Forum for Knowledge-Based Innovation and Sustainable Development)
Current Pharmacogenomics and Personalized Medicine Pigment Epithelium-Derived Factor Prevents Melanoma Growth via Angiogenesis Inhibition
Current Pharmaceutical Design Anionic Host Defence Peptides from the Plant Kingdom: Their Anticancer Activity and Mechanisms of Action
Protein & Peptide Letters Novel Oncogenic Protein Kinase Inhibitors for Cancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Tissue Protective and Anti-Fibrotic Actions of Suramin: New Uses of an Old Drug
Current Clinical Pharmacology Glia: An Important Target for Anti-Inflammatory and Antidepressant Activity
Current Drug Targets In Vitro Evaluation of Antimicrobial and Antiproliferative Activities for Compounds Isolated from the Ficus Bubu Warb. (Moraceae) Fruits: Chemotaxonomic Significance
Drug Delivery Letters Status Epilepticus in the Immature Rodent Brain Alters the Dynamics of Autophagy
Current Neurovascular Research p53 Regulation of Energy Metabolism and Mitochondria Regulation of p53 in Cancer Cells: An Insight into the Role of Manganese Superoxide Dismutase
Current Pharmaceutical Biotechnology Ultrasound-Mediated Cancer Therapeutics Delivery using Micelles and Liposomes: A Review
Recent Patents on Anti-Cancer Drug Discovery Inhibitors for Metastasis Development
Recent Patents on Anti-Cancer Drug Discovery